Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 11/20 | 0.75 |
| ▸ | MMP2 | P08253 | 11/20 | 0.75 |
| ▸ | MMP9 | P14780 | 11/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111222 | 0.87 | MMP1 (0.59) | MMP1MMP2MMP9EGFR | |
| SCHEMBL11648004 | 0.87 | MMP1 (0.70) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL11655853 | 0.87 | MMP1 (0.70) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL2779401 | 0.86 | MEN1 (0.68) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL110012 | 0.86 | MEN1 (0.68) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL13352117 | 0.85 | MMP1 (0.67) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL111095 | 0.85 | SMN1; SMN2 (0.74) | MMP1MMP2MMP9EGFRKDM4E | |
| SCHEMBL21024846 | 0.85 | MMP1 (0.55) | MMP1MMP2MMP9EGFRKDM4E | |
| N-O-Tolylcinnamamide SCHEMBL2593754 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRKDM4E | |
| N-O-Tolylcinnamamide SCHEMBL2593756 | 0.84 | MMP1 (1.00) | MMP1MMP2MMP9EGFRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MMP1 1/4885MMP2 104/4885MMP9 494/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | MMP1 10/4885MMP2 239/4885MMP9 205/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MMP1 1/4885MMP2 104/4885MMP9 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.